149 related articles for article (PubMed ID: 9330778)
1. Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration.
Rohatagi S; Barrett JS; DeWitt KE; Morales RJ
Biopharm Drug Dispos; 1997 Oct; 18(7):567-84. PubMed ID: 9330778
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system.
Rohatagi S; Barrett JS; DeWitt KE; Lessard D; Morales RJ
Biopharm Drug Dispos; 1997 Nov; 18(8):665-80. PubMed ID: 9373724
[TBL] [Abstract][Full Text] [Related]
3. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
[TBL] [Abstract][Full Text] [Related]
4. Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding.
Laine K; Anttila M; Huupponen R; Mäki-Ikola O; Heinonen E
Clin Neuropharmacol; 2000; 23(1):22-7. PubMed ID: 10682227
[TBL] [Abstract][Full Text] [Related]
5. Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males.
Barrett JS; Szego P; Rohatagi S; Morales RJ; De Witt KE; Rajewski G; Ireland J
Pharm Res; 1996 Oct; 13(10):1535-40. PubMed ID: 8899847
[TBL] [Abstract][Full Text] [Related]
6. Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegiline.
Dostert P; Strolin Benedetti M; Persiani S; La Croix R; Bosc M; Fiorentini F; Deffond D; Vernay D; Dordain G
J Neural Transm Suppl; 1995; 45():247-57. PubMed ID: 8748632
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly.
Barrett JS; Hochadel TJ; Morales RJ; Rohatagi S; DeWitt KE; Watson SK; DiSanto AR
Am J Ther; 1996 Oct; 3(10):688-98. PubMed ID: 11862224
[TBL] [Abstract][Full Text] [Related]
8. Toxicokinetic evaluation of a selegiline transdermal system in the dog.
Barrett JS; DiSanto AR; Thomford PJ; Larsen EM; Palazzolo MJ; Morales RJ
Biopharm Drug Dispos; 1997 Mar; 18(2):165-84. PubMed ID: 9099452
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline.
Mascher HJ; Kikuta C; Millendorfer A; Schiel H; Ludwig G
Int J Clin Pharmacol Ther; 1997 Jan; 35(1):9-13. PubMed ID: 9021435
[TBL] [Abstract][Full Text] [Related]
10. Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans.
Heinonen EH; Anttila MI; Karnani HL; Nyman LM; Vuorinen JA; Pyykkö KA; Lammintausta RA
J Clin Pharmacol; 1997 Jul; 37(7):602-9. PubMed ID: 9243353
[TBL] [Abstract][Full Text] [Related]
11. CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline.
Laine K; Anttila M; Nyman L; Wahlberg A; Bertilsson L
Eur J Clin Pharmacol; 2001 May; 57(2):137-42. PubMed ID: 11417445
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse.
Magyar K; Szatmáry I; Szebeni G; Lengyel J
J Neural Transm Suppl; 2007; (72):165-73. PubMed ID: 17982891
[TBL] [Abstract][Full Text] [Related]
13. Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline.
Palovaara S; Anttila M; Nyman L; Laine K
Eur J Clin Pharmacol; 2002 Jul; 58(4):259-63. PubMed ID: 12136372
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline.
Chen L; Shen B; Wang S; Yu Y; Yan H; Shi Y; Duan G; Xiang P
Drug Test Anal; 2019 Jun; 11(6):898-905. PubMed ID: 30614204
[TBL] [Abstract][Full Text] [Related]
15. CYP2D6 polymorphism is not crucial for the disposition of selegiline.
Scheinin H; Anttila M; Dahl ML; Karnani H; Nyman L; Taavitsainen P; Pelkonen O; Bertilsson L
Clin Pharmacol Ther; 1998 Oct; 64(4):402-11. PubMed ID: 9797797
[TBL] [Abstract][Full Text] [Related]
16. Integrated pharmacokinetic and metabolic modeling of ipriflavone and metabolites after oral administration.
Rohatagi S; Barrett JS
Am J Ther; 1997; 4(5-6):189-98. PubMed ID: 10423610
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update.
Mahmood I
Clin Pharmacokinet; 1997 Aug; 33(2):91-102. PubMed ID: 9260033
[TBL] [Abstract][Full Text] [Related]
18. Gas chromatographic procedure for simultaneous determination of selegiline metabolites, amphetamine, methamphetamine and demethyl-deprenyl in pig plasma.
Szebeni G; Lengyel J; Székács G; Magyar K; Gaál J; Szatmári I
Acta Physiol Hung; 1995; 83(2):135-41. PubMed ID: 8588500
[TBL] [Abstract][Full Text] [Related]
19. Quantitative analysis of desmethylselegiline, methamphetamine, and amphetamine in hair and plasma from Parkinson patients on long-term selegiline medication.
Kronstrand R; Ahlner J; Dizdar N; Larson G
J Anal Toxicol; 2003 Apr; 27(3):135-41. PubMed ID: 12731653
[TBL] [Abstract][Full Text] [Related]
20. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole.
Kivistö KT; Wang JS; Backman JT; Nyman L; Taavitsainen P; Anttila M; Neuvonen PJ
Eur J Clin Pharmacol; 2001 Apr; 57(1):37-42. PubMed ID: 11372588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
